On July 23rd, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides for the agency's approved compounding list. BPC-157. TB-500. Semax. Epitalon. Names that spent years living in gray-market marketing copy are now sitting inside a formal regulatory pathway.

Every platform in the space read that as a green light. Almost none of them are asking what still doesn't change.

A Recommendation, Not a Rule

PCAC votes are advisory. The FDA still has to issue a formal rule before any of the six peptides are legally compoundable, and that process runs on its own timeline, the agency's last major action on this list came in 2024, when the committee approved none of the substances it reviewed. Five more peptides, including GHK-Cu and Melanotan II, aren't up for review until February 2027.

What shifted is the direction. What didn't shift is the underwriting question every processor still has to answer before a dollar moves.

The Warning Sign Everyone Skipped Past

Last year's GLP-1 enforcement wave is worth remembering here. It wasn't triggered by compounding status. It came from marketing, claims of equivalence to FDA-approved drugs, compounded products branded without clear manufacturer disclosure. That single wave produced more warning letters than the FDA had sent in the prior decade combined, and it landed on more than 80 telehealth companies.

A favorable vote doesn't change what regulators scrutinize. A faster-moving category tends to draw more attention, not less.

What Underwriting This Category Actually Requires

• Compound-by-compound classification, not category-level approval. Each peptide sits at a different point in the FDA's review, and the list changes as the process moves.

• Prescriber and pharmacy verification, state by state. Licensing is still fragmented, and an advisory vote doesn't touch that.

• A LegitScript-equivalent review of the pharmacy relationship, not just the merchant's own paperwork.

• Marketing claim monitoring, given how the last enforcement wave actually started.

• Age and identity verification at the point of purchase, independent of what's being compounded.

Where the Stack Usually Breaks

Most processors take one of two positions on this category: decline outright, or approve without the underwriting depth it needs. Stripe, PayPal, and Square generally do the former, terminating accounts the moment "peptide" shows up in a business description. What's left is a market of licensed 503A pharmacies, physician-led clinics, and telehealth platforms running on payment infrastructure that either doesn't understand the category or won't touch it.

Built for the Category as It Actually Works

Frame underwrites peptide and compounding merchants against the classification the FDA actually uses, not a blanket high-risk label. Identity verifies prescribers and patients. Sonar monitors for the fraud patterns this category produces. Money Movement and Dispute Management handle the chargeback exposure that comes with high-scrutiny products, without treating a licensed compounding pharmacy the same as an unregulated research-use storefront.

It's the infrastructure already behind merchants operating in this space today, and the one the next wave of platforms will need as the category moves out of the gray zone faster than most of their payment stacks are built for.

The vote changes what's possible. It doesn't change what compliant looks like.